Blue­bird bio dives deep­er in­to its TCR al­liance with Medi­gene, adding $500M in mile­stones and 2 new tar­gets

What­ev­er blue­bird bio $BLUE learned about Medi­gene’s TCR im­munother­a­py tech since it signed up for its ini­tial bil­lion-dol­lar dis­cov­ery pact must have been im­pres­sive. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER